Bright Minds Biosciences Inc. · CSE:DRUG
Bright Minds Biosciences — Investor Day (May 2025)
20 slides from Bright Minds Biosciences's investor day presentation, May 20, 2025
Slide 1: BMB-101 Absence Epilepsy R&D Day
BMB-101 Bright Minds Biosciences Novel 5-HT2C Selective Agonist Absence Epilepsy R&D Day May 20, 2025
Slide 2: Disclaimer and Cautionary Note regarding Forward Looking Statements
Disclaimer and Cautionary Note regarding Forward Looking Statements This corporate presentation (this “Presentation”) of Bright Minds Biosciences Inc. (the “Company”) is (viii) the ability to protect intellectual property rights throughout the world; (ix) market viability for current as of May 2025,
Slide 3: Event speakers
Event speakers Bright Minds Bio Participants Key Opinion Leaders Dennis Dlugos, MD Ian McDonald Professor of neurology and pediatrics at Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania School of Medicine. He is Director of the Section of Clinical Neurophysiology and the
Slide 4: Topics, speakers and timing
Topic Themes Speaker Timing Introduction Ian McDonald 5 min Overview of • Clinical and electrographic presentation (overview) Dennis Dlugos 20 min Absence Seizures • ILAE classification of the Idiopathic Generalized Epilepsy Syndromes & Syndromes • Current treatment paradigm • Absence seizures in DE
Slide 5: Breaking through
BMB-101 Breaking through Novel 5-HT2C Drug resistant epilepsies Selective Agonist Absence seizures
Slide 6: High unmet need beyond Dravet
High unmet need beyond Dravet Addressable targets for BMB-101 range across multiple epilepsies Mixed Acute Seizure Therapy / Prodromes Medically Controllable Other DEE Syndromes Targeted by 70% Dravet fenfluramine TSC Infantile Spasms and bexicaserin Lennox – Gastaul Syndrome Can be EPILEPSY Autoimm
Slide 7: Estimates indicate a total absence prevalence of at least 280K in the USA only
Estimates indicate a total absence prevalence of at least 280K in the USA only US Prevalence of Absence Across Common Epilepsy Syndromes P AT I E NT S WI T H AB S E NCE 74 000 Patients with DEEs have high absence seizure burden 53 500 51 000 30 000 29 500 33 500 7 200 Juvenile Absence Childhood Abse
Slide 8: Opportunity for BMB-101
Opportunity for BMB-101 PCDH19 SYNGAP1 Typical DEEs EMAS Jeavons Absence West seizures Angelman LGS CAE KCNT1 LKS Dravet SCN2A Dup15q Atypical JME Efficacy of branded DEE drugs in Absence seizures is limited Absence or unknown STXBP1 SCN8A seizures JAE GABA modulation may worsen absence seizures DEE
Slide 9: Potential for best-in-class drug in DEE and absence seizures
Potential for best-in-class drug in DEE and absence seizures – Opportunity in All DEEs – Opportunity with Absence Typical Absence Epilepsy All DEE Refractory Market All DEEs ~$21B ~$16B Total JAE LGS Dravet CAE Refractory Other Market TSC DEEs Absence Epilepsy Refractory Market Additional research n
Slide 10: BMB-101 is uniquely positioned to address major unmet needs in epilepsy
BMB-101 is uniquely positioned to address major unmet needs in epilepsy Proof of mechanism The only G protein- Safety and PK/PD Highly selective demonstrated in Ph.1 biased properties validated 5-HT2C agonist Increased gamma- 5-HT2C agonist in Phase 1 power on qEEG Compound 5-HT2A 5-HT2B 5-HT2C $kBB
Slide 11: Preclinical validation in multiple seizure models
Preclinical validation in multiple seizure models BMB-101 Fenfluramine/ INDUCED MODELS Lorcaserin Bexicaserin and analogs Norfenfluramine Mice Electrical (6 Hz) drug- ✓ Not reported ✓ ✓ resistant seizures Maximal Electroshock Seizure (MES) rat/mice model ✓* Not reported ✓ Not reported GENETIC MODELS
Slide 12: Proven mechanism of 5-HT2C agonists in absence epilepsy populations
Proven mechanism of 5-HT2C agonists in absence epilepsy populations Preclinical ü Lorcaserin in GAERS (rat model of absence epilepsies) Clinical Fenfluramine in Sunflower Syndrome (form of absence epilepsy): ü Seizure reduction of >70% in the first cohort ü Cognitive improvements (mean 18-point incr
Slide 13: BREAKTHROUGH – Open Label Phase 2 study
BREAKTHROUGH – Open Label Phase 2 study To Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults Developmental and Epileptic Absence Epilepsy Encephalopathy (DEE) Cohort Cohort 24h EEG: Seizure diary: Efficacy primary Number and duration of electroclinical Major motor seizure frequency
Slide 14: Absence Epilepsy Trial Design
Absence Epilepsy Trial Design Improved approach to measure absence seizures uses 24h ambulatory EEG Dose increase if drug 2 mg/kg BID 12-month Extension is well tolerated 1.67 mg/kg BID EEG Weight-based dosing 1.33 mg/kg BID 1 mg/kg BID 0.67 mg/kg BID Baseline EEG -4 Baseline 0 Titration 4 8 12 Week
Slide 15: What is an absence seizure?
What is an absence seizure? Absence seizure is defined as: • A distinct 3/s spike-and-wave discharge – an abnormal, and unique paroxysmal pattern of a high velocity spike followed by a slower dome shaped wave on the background of a normal EEG. • The 3/s spike-and-wave on EEG is the clinically accept
Slide 16: How are we documenting absence seizures?
How are we documenting absence seizures? Primary Method Exploratory Method 24h EEG Ambulatory Wearable EEG device ü Designed and validated for absence ü Quantitative seizure detection seizure detection ü Potential for sleep assessment ü Convenient absence seizure monitoring NASDAQ: DRUG | BRIGHTMIND
Slide 17: Why are we developing novel drugs for absence seizures?
Why are we developing novel drugs for absence seizures? Absence epilepsies have high unmet need • Current drugs don’t effectively treat all patients and have tolerability and potentially even severe safety issues • The unmet need is in both people with typical absence and those with mixed seizure di
Slide 18: Limited treatment options represent significant opportunity for new branded agent
Limited treatment options represent significant opportunity for new branded agent in the absence treatment paradigm Absence Seizure Management Ethosuximide Absence Seizures+ Absence Seizures only • Standard-of-care drug for CAE - only manages absence seizures (narrow-spectrum) • Associated with GI d
Slide 19: BMB-101 - Potential to reduce the absence seizure burden regardless of epilepsy type
BMB-101 - Potential to reduce the absence seizure burden regardless of epilepsy type • Novel mechanism for the treatment of absence seizures • Potential for best-in-class drug in DEE and first-in-class in absence seizures • Opportunity for once-a-day drug with improved safety • Goal is to improve th
Slide 20: Breaking through – Q&A session
BMB-101 Breaking through Novel 5-HT2C Drug resistant epilepsies Selective Agonist Q&A session